ImmunityBio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 8.27 USD (Oct 30, 2026, 12:41 PM EDT) · Market cap 8.76B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Details
| Name | ImmunityBio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 691 |
| Founded | 2014 |
| Ceo | Richard Adcock |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US45256X1037 |
| Cusip | 45256X103 |
| Cik | 1326110 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Richard Gerald Adcock | President, Chief Executive Officer and Director |
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc. | Founder, Executive Chairman and Global Chief Scientific and Medical Officer |
| David C. Sachs | Chief Financial Officer |
| Regan J. Lauer | Chief Accounting Officer |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer and Director |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
| Sarah Singleton | Chief Communications Officer and Head of Patient Advocacy |
| Emily Arison | Senior Vice President of Human Resources |
| Dr. Leonard S. Sender M.D. | Chief Medical Officer of Liquid Tumors and Cell Therapy |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
Contact
| Address | 3530 John Hopkins Court, San Diego, California 92121, United States |
| Phone | 844 696 5235 |
| Website | https://immunitybio.com |